Cargando…

The Thyroid Pathologist Meets Therapeutic Pharmacology

The effects of many pharmacological agents on thyroid function are well known. Direct influences on measurements of thyroid function tests are also described. However, certain classes of drugs produce morphological changes in the gland. This review focuses on the significance of the following drug c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sande, Christopher M., Tondi Resta, Isabella, Livolsi, Virginia A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890439/
https://www.ncbi.nlm.nih.gov/pubmed/36723855
http://dx.doi.org/10.1007/s12022-023-09749-1
_version_ 1784880947328450560
author Sande, Christopher M.
Tondi Resta, Isabella
Livolsi, Virginia A.
author_facet Sande, Christopher M.
Tondi Resta, Isabella
Livolsi, Virginia A.
author_sort Sande, Christopher M.
collection PubMed
description The effects of many pharmacological agents on thyroid function are well known. Direct influences on measurements of thyroid function tests are also described. However, certain classes of drugs produce morphological changes in the gland. This review focuses on the significance of the following drug classes for the thyroid pathologist: iodine, antithyroid drugs, psychotropic drugs, antibiotics, cardiotropic drugs, antidiabetic drugs, and immunomodulatory agents. Radioactive iodine initially induces mild histologic changes; however, the long-term effects include marked follicular atrophy, fibrosis, and nuclear atypia—changes that vary depending on the pre-therapy condition of the gland. Some psychotropic drugs have been associated with a spectrum of inflammatory changes throughout the gland. The tetracycline class of antibiotics, namely minocycline, can lead to a grossly black thyroid gland with pigment seen in both colloid and follicular epithelial cells while variably present within thyroid nodules. The surgical pathologist most commonly sees an amiodarone-affected gland removed for hyperthyroidism, and the histologic findings again depend on the pre-therapy condition of the gland. While GLP-1 receptor agonists carry an FDA black box warning for patients with a personal or family history of multiple endocrine neoplasia or medullary thyroid carcinoma, the C cell hyperplasia originally noted in rats has not borne out in human studies. Finally, thyroiditis and hypothyroidism are well known complications of checkpoint inhibitor therapy, and rare cases of severe thyroiditis requiring urgent thyroidectomy have been reported with unique histologic findings. In this review, we describe the histologic findings for these drugs and more, in many cases including their functional consequences.
format Online
Article
Text
id pubmed-9890439
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-98904392023-02-01 The Thyroid Pathologist Meets Therapeutic Pharmacology Sande, Christopher M. Tondi Resta, Isabella Livolsi, Virginia A. Endocr Pathol Article The effects of many pharmacological agents on thyroid function are well known. Direct influences on measurements of thyroid function tests are also described. However, certain classes of drugs produce morphological changes in the gland. This review focuses on the significance of the following drug classes for the thyroid pathologist: iodine, antithyroid drugs, psychotropic drugs, antibiotics, cardiotropic drugs, antidiabetic drugs, and immunomodulatory agents. Radioactive iodine initially induces mild histologic changes; however, the long-term effects include marked follicular atrophy, fibrosis, and nuclear atypia—changes that vary depending on the pre-therapy condition of the gland. Some psychotropic drugs have been associated with a spectrum of inflammatory changes throughout the gland. The tetracycline class of antibiotics, namely minocycline, can lead to a grossly black thyroid gland with pigment seen in both colloid and follicular epithelial cells while variably present within thyroid nodules. The surgical pathologist most commonly sees an amiodarone-affected gland removed for hyperthyroidism, and the histologic findings again depend on the pre-therapy condition of the gland. While GLP-1 receptor agonists carry an FDA black box warning for patients with a personal or family history of multiple endocrine neoplasia or medullary thyroid carcinoma, the C cell hyperplasia originally noted in rats has not borne out in human studies. Finally, thyroiditis and hypothyroidism are well known complications of checkpoint inhibitor therapy, and rare cases of severe thyroiditis requiring urgent thyroidectomy have been reported with unique histologic findings. In this review, we describe the histologic findings for these drugs and more, in many cases including their functional consequences. Springer US 2023-02-01 2023 /pmc/articles/PMC9890439/ /pubmed/36723855 http://dx.doi.org/10.1007/s12022-023-09749-1 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Sande, Christopher M.
Tondi Resta, Isabella
Livolsi, Virginia A.
The Thyroid Pathologist Meets Therapeutic Pharmacology
title The Thyroid Pathologist Meets Therapeutic Pharmacology
title_full The Thyroid Pathologist Meets Therapeutic Pharmacology
title_fullStr The Thyroid Pathologist Meets Therapeutic Pharmacology
title_full_unstemmed The Thyroid Pathologist Meets Therapeutic Pharmacology
title_short The Thyroid Pathologist Meets Therapeutic Pharmacology
title_sort thyroid pathologist meets therapeutic pharmacology
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890439/
https://www.ncbi.nlm.nih.gov/pubmed/36723855
http://dx.doi.org/10.1007/s12022-023-09749-1
work_keys_str_mv AT sandechristopherm thethyroidpathologistmeetstherapeuticpharmacology
AT tondirestaisabella thethyroidpathologistmeetstherapeuticpharmacology
AT livolsivirginiaa thethyroidpathologistmeetstherapeuticpharmacology
AT sandechristopherm thyroidpathologistmeetstherapeuticpharmacology
AT tondirestaisabella thyroidpathologistmeetstherapeuticpharmacology
AT livolsivirginiaa thyroidpathologistmeetstherapeuticpharmacology